

July 1, 2023

| | |
|--|--|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|--|--|

Dear Sir / Madam,

Re: Information under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our letter dated May 27, 2023 regarding sale and transfer of all equity shares held by the Company in Auro Vaccines Private Limited, a wholly owned subsidiary of the Company, to Curateq Biologics Private Limited, another wholly owned subsidiary of the Company, as part of verticalization of business operations, we inform you that the said transaction of sale and transfer of shares has been completed and Auro Vaccines Private Limited has become a step down subsidiary of the Company with effect from July 1, 2023.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833
Email: info@aurobindo.com Website: www.aurobindo.com